Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.44 |
| ▸ | WNT3A | P56704 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL711100 | 0.88 | ALDH1A1 (0.53) | SMN1; SMN2KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL31360301 | 0.88 | ALDH1A1 (0.53) | SMN1; SMN2KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL7275882 | 0.85 | SMN1; SMN2 (0.62) | SMN1; SMN2KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL8526121 | 0.82 | TSHR (0.55) | SMN1; SMN2KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL8282238 | 0.79 | RAB9A (0.48) | SMN1; SMN2KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL6616671 | 0.78 | SMN1; SMN2 (0.55) | SMN1; SMN2KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL12766908 | 0.77 | SMN1; SMN2 (0.50) | SMN1; SMN2KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL549253 | 0.77 | MAPT (0.52) | SMN1; SMN2KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL9850270 | 0.77 | RXRA (0.55) | — | |
| SCHEMBL2783283 | 0.76 | KDM4E (0.64) | SMN1; SMN2KDM4EALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300943-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | US | disclosed |
| CN-112334461-A | OGA inhibitor compounds | 詹森药业有限公司 | 2021-02-05 | — | — | CN | disclosed |
| US-20120083495-A1 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, | 2012-04-05 | — | — | US | disclosed |
| US-20120083495-A1 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, | 2012-04-05 | — | — | US | disclosed |
| US-20120083495-A1 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, | 2012-04-05 | — | — | US | disclosed |
| US-8110681-B2 | Compounds for the treatment of spinal muscular atrophy and other uses | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110681-B2 | Compounds for the treatment of spinal muscular atrophy and other uses | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110681-B2 | Compounds for the treatment of spinal muscular atrophy and other uses | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-02-07 | — | — | US | disclosed |
| US-20090312323-A1 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HHS (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312323-A1 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HHS (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312323-A1 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HHS (US) | 2009-12-17 | — | — | US | disclosed |
| EP-2027088-A2 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health (US) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007109211-A2 | 1-OXO-ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109211-A2 | 1-OXO-ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083495-A1 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | SMN1; SMN2, RNMT, CPT1B | SMN1; SMN2 1/4885KDM4E 2775/4885ALDH1A1 1630/4885 |
| US-20210300943-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | SMN1; SMN2 103/4885KDM4E 1495/4885ALDH1A1 3839/4885 |
| US-20090312323-A1 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | SMN1; SMN2, RNMT, CPT1B | SMN1; SMN2 1/4885KDM4E 2632/4885ALDH1A1 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.